JP2025515559A - チカグレロル水溶液、その製造方法および使用 - Google Patents

チカグレロル水溶液、その製造方法および使用 Download PDF

Info

Publication number
JP2025515559A
JP2025515559A JP2024557894A JP2024557894A JP2025515559A JP 2025515559 A JP2025515559 A JP 2025515559A JP 2024557894 A JP2024557894 A JP 2024557894A JP 2024557894 A JP2024557894 A JP 2024557894A JP 2025515559 A JP2025515559 A JP 2025515559A
Authority
JP
Japan
Prior art keywords
ticagrelor
aqueous
solution
cyclodextrin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515559A5 (cg-RX-API-DMAC10.html
Inventor
パティル,アトゥル
Original Assignee
ヒロリス デベロップメンツ エス アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/063185 external-priority patent/WO2023222184A1/en
Application filed by ヒロリス デベロップメンツ エス アー filed Critical ヒロリス デベロップメンツ エス アー
Publication of JP2025515559A publication Critical patent/JP2025515559A/ja
Publication of JP2025515559A5 publication Critical patent/JP2025515559A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024557894A 2022-05-16 2023-05-16 チカグレロル水溶液、その製造方法および使用 Pending JP2025515559A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2022/063185 WO2023222184A1 (en) 2022-05-16 2022-05-16 Aqueous ticagrelor solution, method of manufacturing and uses
EPPCT/EP2022/063185 2022-05-16
EPPCT/EP2023/055736 2023-03-07
EP2023055736 2023-03-07
PCT/EP2023/063071 WO2023222660A1 (en) 2022-05-16 2023-05-16 Aqueous ticagrelor solutions, method of manufacturing and uses

Publications (2)

Publication Number Publication Date
JP2025515559A true JP2025515559A (ja) 2025-05-20
JP2025515559A5 JP2025515559A5 (cg-RX-API-DMAC10.html) 2026-05-14

Family

ID=86604209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557894A Pending JP2025515559A (ja) 2022-05-16 2023-05-16 チカグレロル水溶液、その製造方法および使用

Country Status (9)

Country Link
US (1) US20250235455A1 (cg-RX-API-DMAC10.html)
EP (1) EP4525931A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025515559A (cg-RX-API-DMAC10.html)
KR (1) KR20250024925A (cg-RX-API-DMAC10.html)
CN (1) CN119212736A (cg-RX-API-DMAC10.html)
AU (1) AU2023271339A1 (cg-RX-API-DMAC10.html)
CA (1) CA3252689A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024013807A (cg-RX-API-DMAC10.html)
WO (1) WO2023222660A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260113060A (ko) * 2023-11-16 2026-07-21 하이로리스 디벨롭먼츠 에스에이 피부경유 관상동맥 중재술 (pci)을 겪은 환자에서 허혈성 사건의 치료, 감소 또는 예방에 사용을 위한 티카그렐러 iv
WO2025104274A1 (en) * 2023-11-16 2025-05-22 Hyloris Developments Sa Ticagrelor iv for use in the prevention of thromboembolic events
AU2024386725A1 (en) * 2023-11-22 2026-04-30 Hyloris Developments Sa Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake
CN117919246A (zh) * 2024-01-26 2024-04-26 重庆东得医药科技有限公司 一种以左西孟旦为活性成分的组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3100728T3 (pl) * 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
CN110917167A (zh) * 2018-09-19 2020-03-27 河南天晟泰丰医药科技有限公司 替格瑞洛肠溶缓释软胶囊及其制备方法
WO2021096444A1 (en) * 2019-11-13 2021-05-20 Santa Farma İlaç Sanayi̇ A.Ş. Pharmaceutical compositions comprising ticagrelor

Also Published As

Publication number Publication date
CN119212736A (zh) 2024-12-27
US20250235455A1 (en) 2025-07-24
EP4525931A1 (en) 2025-03-26
WO2023222660A1 (en) 2023-11-23
CA3252689A1 (en) 2023-11-23
KR20250024925A (ko) 2025-02-20
MX2024013807A (es) 2025-02-10
AU2023271339A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US12383622B2 (en) Pre-mixed, ready-to-use pharmaceutical compositions
JP7489965B2 (ja) マルチキナーゼ阻害剤のエマルジョン製剤
EP4525931A1 (en) Aqueous ticagrelor solutions, method of manufacturing and uses
WO2023222184A1 (en) Aqueous ticagrelor solution, method of manufacturing and uses
CA2486571C (en) Pharmaceutical composition
AU2024381796A1 (en) Ticagrelor iv for use in the treatment, reduction or prevention of an ischemic event in a patient undergoing a percutaneous coronary intervention (pci)
JP2026509786A (ja) グラム陽性菌血症の治療に使用するチカグレロール静脈内製剤
WO2025104274A1 (en) Ticagrelor iv for use in the prevention of thromboembolic events
AU2024386725A1 (en) Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake
US20250114342A1 (en) Apixaban oral liquid dosage forms
WO2025051399A1 (en) Liquid ticagrelor formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260501